Abstract
Introduction
The initial public offering (IPO) market for biotech and specialty pharma
companies has been nearly lifeless in 2008. Investment bankers are unimpressed
by the performance of these companies, and money managers are reluctant to
support a negative trend. The other side of intense pessimism, however, is
that money accumulates on the sidelines where life science investors
ultimately become impatient with money market returns and look for places to
put risk capital to work. We demystify the best way to navigate the startup
route through three in-depth Spectrum Expert Commentaries. A fresh and
comprehensive look at IPOs and industry trends demonstrates that the future is
not all bleak.
Get the Answers You Need to Shape Your Strategy
- Having raised enough money, filed the sufficient forms, and ensured your
leading compound is in the intended phase of development are all important
factors in the decisions companies make before going public. What steps, when
implemented, will further the likelihood of a successful IPO filing? How can
competitors' strategies be interpreted based on their decisions?
- Despite the unstable state of today' s economy, not every startup is aiming
to be acquired by a larger firm. What exit strategies are particularly common
among those biotech startups that are performing well? What motivates the
investors that are observing from the sidelines?
- Expert opinion is unanimous: establishing a strong game plan early in the
process of the pathway to going public - and sticking to it - is essential.
How can a biopharma or diagnostics company looking to invest in a startup
influence that process to create a win-win for all parties involved?
Scope
- Overview of the biotechnology startup landscape: market overview,
market performance, 2007- 2008 IPOs, status of startups' lead compounds in
development.
- Company profiles: detailed company profiles of six startups that
are making strides in today' s tough economy - Molecular Insight
Pharmaceuticals, NeurogesX, NovaBay Pharmaceuticals, Optimer Pharmaceuticals,
Orexigen Therapeutics, and Rosetta Genomics.
- Spectrum Expert Commentaries: in-depth analysis from innovative,
accomplished, and renowned scientist entrepreneurs who provide valuable
strategic insight and advice to early-stage companies.
- Specific insight for young companies: advice on how to plan for the
IPO road show; issues to consider regarding investor relations; and the
advantages of a strong management team.
|
Related Report
|
View Cart
